TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Health Issues HCR

Coronavirus Aid, Relief & Economic Stability Act (CARES Act) and other legislative proposals related to the COVID-19 crisis; HR 3199-Terminating the Extension of Rights Misappropriated Act of 2019; S.64-Preserve Access to Affordable Generic & Biosimilars Act; HR 1499-Protecting Consumer Access to Generic Drugs Act; HR 1344-Competitive Drugs Act of 2019; HR 938-Bringing Low Cost Options & Competition While Keeping Incentives for New Generics Act ("BLOCKING Act"); HR 1506-Fair & Immediate Release of Generic Drugs Act; HR 1520-Purple Book Continuity Act; HR 1503-Orange Book Transparency Act; S.344/HR 990-Hatch-Waxman Integrity Act; Stronger Patents Act; S.1895-Lower Health Care Costs Act; S. 2543-Prescription Drug Pricing Reduction Act; HR 3-Elijah E Cummings Lower Drug Costs Now Act; and Administration review of drug pricing policies.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); White House Office; State, Dept of (DOS)

Bills named: H.R. 1499 (116th), H.R. 3199 (116th), H.R. 990 (116th), H.R. 1520 (116th), S. 2543 (116th), H.R. 1344 (116th), S. 64 (116th), S. 344 (116th), H.R. 1506 (116th), S. 1895 (116th), H.R. 1503 (116th), H.R. 3 (116th), H.R. 938 (116th)

Trade (domestic/foreign) TRD

Foreign export restrictions pertaining to India and Italy

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

Contacted: State, Dept of (DOS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Health & Human Services, Dept of (HHS)